Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT00075881 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

44

Enrollment

NIH

Sponsor class

Conditions

Stage I Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma

Interventions

DRUG: bortezomib
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)